CJD-tainted blood- and plasma-derivatives should be recalled, FDA ad hoc committee recommends.
CJD-TAINTED BLOOD- AND PLASMA-DERIVED PRODUCTS SHOULD BE WITHDRAWN, FDA's Ad Hoc Advisory Committee on Creutzfeldt- Jakob Disease decided at its inaugural meeting June 22 in Bethesda, Md. On a vote of 12-0 with one abstention the committee determined that blood components "from donors who are diagnosed with CJD" should be withdrawn; the vote shifted to 10-2 with one abstention on the withdrawal of "implicated plasma derivatives."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth